## AZN: AstraZeneca PLC - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.06 indicates fundamental undervaluation. Quality metrics strong (ROE 22%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($88.64)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. The Truth About AstraZeneca plc: Why Everyone Is Suddenly Paying Attention**
- Source: AD HOC NEWS | 20260105T025837 | Bullish | Relevance: 100%
- AstraZeneca plc is gaining attention as a must-watch stock due to its viral science, real revenue, and robust pipeline in oncology, cardiovascular, metabolic, and respiratory treatments, moving beyond its vaccine-era reputation. While not a "meme rocket," its steady, large-cap performance and dividend-paying track record make it an attractive long-term hold for investors seeking stability and diversified growth rather than short-term speculative gains. The article emphasizes its strong business fundamentals, R&D spend, and global presence, positioning it as a strong contender against rivals like Pfizer for multi-year growth.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.06 suggests fair value with growth premium. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $282.8B |
| Beta | 0.19 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.06 |
| Forward P/E | 17.7 |
| Current P/E | 19.9 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.2% to -0.2% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). RSI neutral at 52. OFD pattern: +DLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.25% (CS: 38) | Neutral |
| RSI_14 | 52.2 | Neutral |
| MACD Histogram | -0.19 | Bearish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 1.027x | Above |
| vs SMA200 | 1.171x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $91.22
- **Stop Loss:** $88.64 (2.8% risk)
- **Target:** $96.38 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 334
- **Position Value:** $30,467.48
- **Portfolio %:** 30.47%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*